TOP > 外国特許検索 > PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS NEW

外国特許コード F180009537
整理番号 (S2017-0260-N0)
掲載日 2018年11月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP000531
国際公開番号 WO 2018131662
国際出願日 平成30年1月11日(2018.1.11)
国際公開日 平成30年7月19日(2018.7.19)
優先権データ
  • 特願2017-002962 (2017.1.11) JP
発明の名称 (英語) PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS NEW
発明の概要(英語) This prophylactic and/or therapeutic agent for diseases associated with AMPA receptors contains a compound represented by formula (I), or a pharmaceutically acceptable salt or solvate thereof. (In the formula, A and Z independently represent CO, SO or SO2; X and Y are independently S or O; R1-R4 are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group or a halo group; R5 is, independently for each occurrence, an alkyl group, an alkenyl group, an alkynyl group or a halo group; and n is an integer of 0-4).
従来技術、競合技術の概要(英語) BACKGROUND ART
AMPA receptor molecule is a synaptic function, play an important role in the spirit of the neural activity.The inventors of the present invention in vivo (glutamate receptor) AMPA receptor synaptic transfer, including memory and learning various higher order brain functions in molecular and cellular mechanisms of plastic phenomenon has been revealed that the (non-patent document 1-8).In addition, in recent years mainly AMPA receptors in postmortem brain research depression, schizophrenia, drug abuse, autism, epilepsy disease, ALS the spirit and many others, can be associated with a neurological disease have been reported.AMPA receptor agonist of the target disease such as a preclinical, clinical development has been actively performed.AMPA receptor drug target (AMPA receptor agonist) are roughly classified into the receptor antagonist (2) receptor function in the presence of active agents (1).With respect to the former, with respect to the disease epilepsy AMPA receptor antagonists in the March 2016 (ficompa; Inc. eisai co., ltd.) and marketed in Japan.On the other hand, AMPA receptor function activators are still not available on the market.The onset of the disease mechanism and the heteroatom, AMPA receptor agonist is effective in all considered to be not much higher possibility.Therefore, the activation action of the AMPA receptor function in the development of a pharmaceutical composition containing a compound has been required.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
  • 発明者(英語)
  • TAKAHASHI TAKUYA
  • MIYAZAKI TOMOYUKI
  • NAKAJIMA WAKI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close